Objective: Here, we report the clinical results of iridium-192 high dose rate brachytherapy at Kanazawa University Hospital. Methods: The study population consisted of 166 patients diagnosed with T1c-T3bN0M0 prostate cancer treated with high dose rate brachytherapy and external beam radiotherapy and followed up for 6 months or longer. Treatment consisted of external beam radiotherapy to the prostate at 44 Gy/22 fractions and high dose rate brachytherapy at 18 Gy/3 fractions. Results: Median follow-up interval was 31.5 months (range 6.2 -88.7). The overall 5-year biological recurrence-free survival rate was 93.0%. The 5-year biological recurrence-free survival rates for the patients in low-, intermediate-and high-risk groups according to the D'Amico risk classification criteria were 96.1%, 89.0% and 91.6%, respectively. When limited to the group that did not receive adjuvant hormonal therapy, the 5-year biological recurrence-free survival rates for the patients in low-, intermediate-and high-risk groups were 96.0%, 96.3% and 82.9%, respectively. Grade 3 or greater adverse effects were rare. Urethral stricture was observed in only 1.0% of the patients. Eighty percent of patients retained erectile function after high dose rate brachytherapy and reported satisfaction with sexual function. Conclusions: High dose rate brachytherapy is considered a good form of treatment for localized prostate cancer, although longer follow-up is necessary.
INTRODUCTION
Recently, the number of prostate cancer (PCa) patients has been increasing in Japan because of the aging of society and the widespread adoption of prostate-specific antigen (PSA) screening (1) . There has been an especially notable increase in the rate of identification of localized PCa according to adoption of PSA screening (1) . Radical prostatectomy (RP) or radiation therapy (RT) is often performed for localized PCa in young men, and hormonal therapy (HT) is often performed in older men. Treatment outcome of RP for localized early-stage PCa is good, but this therapy has a number of drawbacks. This procedure is more invasive than other forms of therapy, biochemical recurrence-free survival (bRFS) decreases in high-risk patients (2, 3) and there is a high incidence of adverse effects, such as urinary incontinence and erectile disorder (4, 5) . On the other hand, HT is well tolerated, and many patients of advanced age can receive this therapy. However, this therapy has a number of adverse effects, such as erectile disorder, hot flashes and osteoporosis (6 -8) . In addition, the outcome of HT is poorer than that of RP and RT (9) .
RT includes several methods. As the recurrence rate of external beam radiotherapy (EBRT) monotherapy is higher than that of RP, dose escalation is necessary to improve relapse-free survival (10) . Several alternative methods have been developed to escalate the radiation dose of the prostate without increasing adverse effects, including threedimensional conformal EBRT and intensity-modulated radiation therapy. Brachytherapy is also one of these methods and can be divided into permanent prostate implant (PPI) and high dose rate brachytherapy (HDR-BT). Sophisticated PPI was reported, and many patients have received PPI in Europe and the USA (11) . Today, PPI has achieved very good results almost equivalent to those of RP (10, 12, 13) . In Japan, many institutions have begun PPI using 125 I seeds since this therapy was approved for medical insurance in 2006. On the other hand, HDR-BT was first performed in 1986 at Keil University in Germany to improve the uncertainty of dose distribution in PPI and minimize exposure of staff to radiation. At present, in Japan, only about 10 institutions are performing HDR-BT because of the high investment required for equipment. However, HDR-BT has recently been suggested to be suitable for localized PCa treatment because PCa has a low a/b ratio (14 -17) .
At Kanazawa University Hospital, HDR-BT has been performed and 246 patients were treated between February 1999 and May 2007. Previously, we reported the usefulness of this treatment method in 97 patients (18) . However, the median follow-up was short and the number of patients was small in this previous study. Therefore, we performed an updated analysis of outcome of this treatment to examine the usefulness of HDR-BT in the present study.
PATIENTS AND METHODS
In our institution, HDR-BT was indicated non-metastasized PCa with any T stage. The present study population consisted of 166 patients diagnosed with T1c-T3bN0M0 PCa according to the 1997 International Union Against Cancer TNM classification who underwent HDR-BT and EBRT between February 1999 and December 2005, and had been followed up for 6 months or longer. Staging pelvic lymphadenectomy was recommended in patients in whom the probability of lymph node metastasis by Partin's nomogram (19) exceeded 5%. Neoadjuvant hormone therapy (NAHT) was performed to reduce the prostate volume (,30 ml) and prevent disease progression while awaiting treatment. Adjuvant hormone therapy (AHT) was recommended in patients who satisfied at least two of the three criteria: clinical stage !T2b, Gleason score (GS) !8 and PSA !20 ng/ ml. The content of hormone therapy was decided by the family doctor.
Treatment consisted of EBRT (four ports) to the prostate in 22 fractions of 2.0 Gy to a total dose of 44.0 Gy and HDR-BT using a 192 Ir microselectron (Nucletron) in 3 fractions of 6.0 Gy within 24 h to a total dose of 18.0 Gy. HDR-BT was performed by inserting about 10 -12 (maximum 17) applicator needles into the prostate using a template under transrectal ultrasound guidance under spinal anesthesia. Next, computed tomography (CT) was performed, and a therapeutic plan was created using the obtained CT scan images. We drew the contours of the prostate and performed dose evaluation with margins of about 3 mm. The applicator needles remained inserted during the 24 h irradiation period. The planning target volume (PTV) was defined as the prostate gland with or without proximal seminal vesicle. The reference point for PTV was set 5 mm behind the needle nearest to the rectal wall. The treatment was optimized using a geometric optimization program with or without a manual optimization. Rectal and urethral dose was controlled within 75% and 150% of PTV, respectively.
After treatment, patients were followed up by monitoring the urinalysis and PSA level every 3 months. Digital rectal exam, transrectal ultrasonography, bone scan and CT (chest and abdomen) were performed if the episode of PSA elevation was occurred. Adverse effects were recorded according to the Common Terminology Criteria for Adverse Events v3.0 from the National Cancer Institute (20) . In addition, we compared the International Prostate Symptom Score (IPSS) and International Index of Erectile Function 5 (IIEF5) between pre-and post-treatment (12 months after treatment) to evaluate the effects of urinary symptoms and sexual function.
In the present study, recurrence was defined by two types: biochemical recurrence and clinical recurrence. Clinical recurrence was determined by clinical evidence of recurrence (e.g. detection of metastasis on CT scan or bone scintigraphy). Biochemical recurrence was determined according to the Houston criteria (21), i.e. when the first PSA rise of at least 2 ng/ml greater than the nadir was observed. The RFS curves were calculated by the Kaplan -Meier method in all cases and in the cases that did not receive AHT (non-AHT group). Moreover, the patient group was divided into subgroups according to the D'Amico risk classification criteria (22) , and RFS was also evaluated in each group by the Kaplan -Meier method (we included patients of clinical stage T3 in high-risk group). We also limited the patients to the high-risk group, divided into subgroups with regard to whether AHT was performed or not (AHT and non-AHT groups) and calculated RFS curves. Furthermore, we divided the patients into two subgroups that satisfied two or more D'Amico high-risk criteria or not, and calculated RFS curves. Statistical significance was calculated using the log-rank test. Two-sided P values of ,0.05 were regarded as statistically significant.
RESULTS
The patients' clinical background data are shown in Table 1 No patients died of PCa. The clinical recurrence was observed in only one patient after biochemical recurrence. Figure 1 shows the biochemical RFS (bRFS) curves calculated by the Kaplan -Meier method. The overall 5-year bRFS rate was 93.0%. The 5-year bRFS rates for the patients in low-, intermediate-and high-risk group were 96.1%, 89.0% and 91.6%, respectively. When limited to the non-AHT group, the 5-year bRFS rates for patients in the low-, intermediate-and high-risk groups were 96.0%, 96.3% and 82.9%, respectively. Table 2 shows the characteristics of the high-risk patients. AHT was performed in about half of the cases, and the rate of AHT tended to be greater in the higher-risk cases. Twenty-five cases in the AHT group, but only five cases in the non-AHT group, satisfied at least two of the following criteria: clinical stage !T2b, GS !8 and PSA !20 ng/ml. Figure 2A shows bRFS curves for high-risk patients. If the patient received AHT, no recurrence was observed. In the non-AHT group, the 5-year bRFS rate was 82.9%. Figure 2B shows bRFS curve for the non-AHT group (36 patients). The 5-year bRFS rate was 91.7% in patients with only one risk factor and 50.0% in those with two or more risk factors (P ¼ 0.08).
The perioperative complications were as follows: urinary retention in seven cases, blood transfusion after removing the needles in three cases, peroneal nerve paralysis for unknown reason in two cases, and delirium and perforation of the peritoneum in one case. These complications occurred mostly in the early study period and there were no such complications in recent study.
We obtained both acute and late toxicities in 97 patients (Table 3) . Rectal toxicity, such as proctitis and diarrhea, was rare. G1 or G2 adverse effects occurred at rates of less than 7% in both acute and late phases, and there were no cases of !G3 rectal toxicity. On the other hand, urinary toxicity such as pollakisuria and dysuria was frequent. Pollakisuria occurred in more than half of all cases in acute phase, but there were no cases with !G3 toxicity. Dysuria occurred in 24% of cases but !G3 toxicity occurred at a rate of only 1.0%, which required temporary catheterization. In late phase, the frequencies of pollakisuria and dysuria decreased to 21.9% and 5.2%, respectively. Urethral stricture requiring urethrotomy (G3 dysuria) occurred only in one case (1.0%).
We obtained pre-and post-IPSS and IIEF5 score in 110 patients. Figure 3 shows the IPSS before and after treatment. There were only slight changes in all questions and total score after 1 year of treatment. (Fig. 4A shows a comparison of the total IIEF5 score between pre-and post-treatment in the non-AHT group.) In addition, Fig. 4B shows a comparison of the mean IIEF5 score divided into each question in the non-AHT group. The mean score decreased slightly in all five questions; especially, in Question 5 (satisfaction with sexual intercourse), about 80% of patients who responded with !2 points before treatment also gave a response of !2 points after HDR-BT (Fig. 4C) . 
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reported that the 5-year bRFS rates for patients in low-, intermediate-and high-risk groups according to the D'Amico risk classification were 90%, 87% and 69%, respectively. The protocol of this study was 22 -24 Gy/4 fraction of HDR-BT and 36 Gy of EBRT without AHT. In all previous reports, the 5-year bRFS rates for patients in low-, intermediate-and high-risk group were 90%, 90% and 60%, respectively. Although it is not possible to compare our results with those of other studies because of the differences in patient backgrounds and treatment protocols, the 5-year bRFS rates for patients in the low-, intermediate-and high-risk groups in the present study were 96.1%, 89.0% and 91.6%, respectively. The good results can be explained by the combined use of HT, although the irradiation dose in our protocol was lower than in previous studies. In the present study, NAHT was performed in 135 patients (81%) and AHT was performed in 47 patients (28%). AHT was performed in 37 patients in the high-risk group, which corresponded to about half of the patients in this group. The 5-year RFS rates of the high-risk non-AHT and AHT groups were 82.9% and 100%, respectively. When limited to the non-AHT group, the 5-year RFS rates were 91.7% and 50% for patients with only one risk factor and with two or more risk factors according to the D'Amico risk classification, respectively. Therefore, we concluded that additional therapy is needed in cases with two or more risk factors; however, the number of cases was small and there was no significant difference between the two groups. In the present study, we performed AHT in such patients. Dose escalation should be considered in high-risk patients because it may improve outcome in cases of unfavorable PCa (25) . However, HT is considered to be more effective in cases in which distant micrometastases are thought to already be present at the time of primary therapy. As median follow-up time was still short, it will be necessary to examine the outcome with a longer median follow-up time in future studies.
Adverse effects were slight in this study, and G3 or more severe adverse effects occurred only rarely. Urethral stricture occurs in 0 -14% of cases after HDR-BT (23,24,26 -29) . It was thought that movement of the applicator needles causes an increase in dose in the bulbar urethra and results in urethral stricture (30 -32) . However, urethral stricture occurred at a rate of only 1.0% in the present study because our HDR-BT protocol was 6 Gy Â 3 fractions, which was lower than in other studies. Because we slightly decreased the dose to the apex of the prostate and we carefully check the movement of brachytherapy-needles at every time of irradiation, we could reduce the occurrence rate of urethral stricture. Although the average values of IIEF5 were already low before NAHT and HDR-BT, 80% of the patients in the non-AHT group retained erectile function after HDR-BT and reported satisfaction with their sexual life. Grills et al. (33) reported a post-HDR-BT erectile dysfunction rate of 16%, which was almost the same as in our study. On the other hand, Grills et al. (33) also reported that rate of impotence 3-year after treatment was lower in cases of HDR-BT (16%) than in those with a PPI (45%). In addition, post-operative erectile dysfunction occurred in 56% of the patients even in Table 3 . Jpn J Clin Oncol 2010;40(7) 681 nerve-sparing RP (34) . These reports and the results of the present study suggested that HDR-BT produces less adverse effects than RP and PPI. However, HDR-BT also has the limitation that the patients require complete rest in bed during the treatment period to avoid damage to the perineum and applicator movement as the connector end of the applicator and the template protrude from the perineal skin. It is therefore less convenient for patients and there is an increased risk of deep vein thrombosis. Initially, patients experienced severe perineal pain after the effect of the spinal anesthesia was diminished. Now, however, additional continuous epidural anesthesia has reduced the pain and contributed to improvement of quality of life around the time of treatment. Moreover, Yoshida et al. (35) reported improvement of quality of life around the time of treatment, making it possible to walk unaided in patients undergoing HDR-BT. With improvement of the disadvantages of HDR-BT with these new devices, this type of therapy may become the best choice of treatment for localized PCa.
CONCLUSIONS
We reported an updated analysis of the outcome of HDR-BT. In the present study, we obtained good results 
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Clinical results of iridium-192 HDR-BT with EBRT with a 5-year RFS rate of 93.0%. Even when limited to the high-risk group, the 5-year RFS rate was 82.9% in the non-AHT group and 100% in the AHT group. Adverse effects were slight, with urethral stricture occurring in only 1.0% of the patients and 80% of the patients in the non-AHT group retaining erectile function with satisfaction of sexual life. HDR-BT is considered a good form of treatment of localized PCa, although further studies with longer follow-up are necessary.
